1 active not recruiting, 1 completed. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Resectable Soft Tissue Sarcoma: new trials by email Literature Review of Resectable Soft Tissue Sarcoma trials Research Report on Resectable Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Definitive Surgical Resection, Nanoplexed Poly I:C BO-112, Nivolumab - Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 14 | 2020-10-14 | 2026-03-10 |
| Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma Navtemadlin, Radiation Therapy, Surgical Procedure - Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2018-06-20 | 2025-09-23 |
Sarcoma (2) · Dermatofibrosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Neurofibrosarcoma (1) · Sarcoma, Synovial (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective and Soft Tissue (2) · Fibrosarcoma (1) · Histiocytoma (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Fibrous Tissue (1) · Neoplasms, Muscle Tissue (1) · Neoplasms, Nerve Tissue (1) · Nerve Sheath Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Neurofibroma (1) · Neuromuscular Diseases (1) · Peripheral Nervous System Diseases (1)
Radiation (2) · Radiotherapy (2) · 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · BO-112 (1) · Nivolumab (1) · Surgical Procedures, Operative (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1)
Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (2)
Meng X Welliver (1) · Vishruth Reddy, MD, PhD (1)
K08CA245181 (1), U10CA180868 (1)